Patient-Reported Outcomes of Ugandans Living with Autoimmune Rheumatic Diseases

Short title: PROMs in Rheumatology Clinics in Uganda

Felix Bongomin^{1,2*}, MB ChB, M.Sc., FECMM, Maria Sekimpi¹, MB ChB, Barbra Natukunda¹, MB ChB, Anthony Makhoba^{3,4}, MB ChB, M.MED, and Mark Kaddumukasa¹, MB ChB, M.MED, PhD

1. Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda
2. Department of Immunology and Medical Microbiology, Gulu University Medical School, Gulu, Uganda
3. Department of Medicine, St. Francis's Hospital- Nsambya, Kampala, Uganda
4. Department of Medicine, Mother Kevin Postgraduate Medical School, Uganda Martyrs University, Kampala, Uganda

*Correspondence

Felix Bongomin, MB ChB, MSc, FECMM
Email: drbongomin@gmail.com
Tel: + 256 -784-523-395

25 Abstract

26 **Purpose:** This study aimed to assess the patient-reported outcomes (PROs) in
27 rheumatic patients attending two tertiary rheumatology clinics in Uganda.

28 **Methods:** A cross-sectional, clinical audit of patients aged 16 years or older with a
29 confirmed diagnosis of rheumatic disease and receiving disease modifying anti-
30 rheumatic drugs (DMARDs) was conducted between September and December
31 2020. Health index and overall self-rated health status were assessed using the ED-
32 5D-5L tool. Comparisons for variables was performed using Student's t-test or Mann-
33 Whitney U for continuous numerical data while categorical data was compared using
34 either χ^2 tests or Fisher's exact tests as appropriate.

35 Results:

36 We enrolled 74 eligible patients: 48 (64.9%) had rheumatoid arthritis (RA), 14
37 (18.9%) had systemic lupus erythematosus (SLE), and 12 (16.2%) had other
38 autoimmune rheumatic disorders. Majority (n=69, 93.2%) were female with a mean
39 $\pm$ SD age of 45 ± 17 years. Fourteen (18.9%) patients were on concomitant herbal
40 medication while using DMARDs and 26 (35.1%) self-reported at least 1 adverse
41 drug reactions to the DMARDs. Any level of problem was reported by 54 (72.5%)
42 participants for mobility, 47 (63.5%) for self-care, 56 (75.6%) for usual activity, 66
43 (89.1%) for pain and discomfort, and 56 (75.6%) for anxiety/depression. Patients
44 with SLE had higher median health index compared to those other autoimmune
45 rheumatic disorders ($p < 0.0001$). Overall self-rated health status was comparable
46 across clinical diagnoses ($p = 0.2$), but better for patients who received care from
47 private (Nsambya Hospital) compared to public hospital (Mulago Hospital) (65 vs. 50,
48 $p = 0.009$).

49 **Conclusion:** There is a substantial negative impact of autoimmune rheumatic
50 diseases on quality of life of patients, especially those receiving care from a public
51 facility in Uganda.

52 **Keywords:** Autoimmune rheumatic diseases, SLE, rheumatoid arthritis, Health
53 index, patient-reported outcomes, DMARDs, Uganda

54

55 Clinical Significance

- 56 1. Adverse drug reactions to DMARDs was reported by more than one-third of
57 the patients
- 58 2. SLE patients have better quality of life compared to patients with other
59 autoimmune rheumatic disease.
- 60 3. Concomitant use of herbal medication is common and associated with lower
61 health index and lower overall self-rated health status.
- 62 4. Autoimmune rheumatic diseases impose a heavy financial burden on affected
63 patients, over 70% of the study patients required financial support for
64 management of their disease and a high proportion of these patients were not
65 on their DMARD therapy the week prior to their scheduled clinic appoints.

66

67

68

69

70

71 Introduction

72 Autoimmune rheumatic disorders such as rheumatoid arthritis (RA) and systemic
 73 lupus erythematosus (SLE) are associated with pain, disability and several co-
 74 morbid conditions thus significantly impacting on quality of life and overall wellbeing
 75 of the affected individuals and their families.¹ Consequently, higher morbidity and
 76 mortality rates are observed among these individuals compared to the general
 77 population ^{1,2}. Also, there's a significant individual differences in the day-to-day
 78 variability of pain, fatigue, and well-being in patients with rheumatic disease.³
 79 Therefore, quality of life is central in the care of patients with autoimmune rheumatic
 80 diseases and is an important target in therapeutic advances in rheumatology while
 81 evaluating or managing these patients with disease modifying anti-rheumatic drugs
 82 (DMARDs) .⁴

83 Patient-reported outcomes (PROs) are patient's perspectives on their disease
 84 activity, functional status, and quality of life ⁵. Patient-reported outcome measures
 85 (PROMs), are a set of widely available tools directly capture PROs and are
 86 increasingly being used in clinical rheumatology practice and in research to help
 87 inform patient-centered care and clinical decision-making even among vulnerable
 88 rheumatic patients such as those with low health literacy or English proficiency.⁶

89 There are no locally validated rheumatic disease specific PROMs in Africa and data
 90 on PROs of patients with rheumatic diseases in Africa is scanty, even though these
 91 diseases, especially RA and SLE are increasingly being reported in Africa.⁷⁻⁹ This
 92 study aimed to describe PROs of patients with autoimmune rheumatic diseases in
 93 two tertiary care centers in Uganda.

94 Patients and Methods

95 *Study design and settings*

96 This descriptive, cross-sectional clinical audit recruited consecutive outpatients
 97 attending two rheumatology clinics at Mulago National Referral Hospital (Mulago
 98 Hospital), Kampala, Uganda and St. Francis's Hospital-Nsambya, Kampala, Uganda
 99 (Nsambya Hospital) between September and December 2020. Mulago Hospital,
 100 located in the capital city, Kampala, is the largest public health facility in Uganda

serving as a national super-specialized hospital with over 1,000-bed capacity. Nsambya Hospital is a faith-based, private-not-for-profit hospital also located in Kampala, Uganda.

Study population

Patients aged 16 years or older with a diagnosis of an autoimmune rheumatologic disease diagnosed by one of the two experienced rheumatologists (AM and MK) for whom at least one of the DMARDs was prescribed in their last previous clinic visit constituted the study population.

Data collection

Data were collected using semi-structured questionnaires administered by the treating physicians (the authors) during routine clinical care. This audit was anonymous, consisted of semi-structured questions, which were available only in English. Data was collected on the following parameters: (1) patient socio-demographic characteristics: age, gender, marital status, level of education, current employment status, monthly income and financial support from family members; (2) Clinical diagnosis: duration of illness, self-reported disease severity, disease flares, hospitalization and family history of autoimmune disease; (3) Medication: DMARDs used, duration of therapy, source of DMARDs, monthly expenditure on DMARDs, satisfaction with treatment, concomitant use of herbal medication, adverse drug reactions; (4) Number of additional medications used daily; and (5) co-morbidities

Patient-reported outcome measure

The EQ-5D-5L, a standardized instrument for use as a measure of health outcomes consisting of 5 dimensions and 5 levels was administered to the participants¹⁰. The tool has been previously used in sub-Saharan Africa and is being validated in Ethiopia^{11,12}. The 5 dimensions assessed were mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels (no problems, slight problems, moderate problems, severe problems, extreme problems/unable to). Health state profile was generated from these dimensions and levels. Overall self-rated health status was assessed using the visual analogue scale

(VAS) on which the patient rates his/her perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).

Data analysis

Baseline characteristics were summarized using medians and ranges or means and standard deviations (SD) for continuous variables and frequencies and percentages for categorical variables. Comparisons for variables were performed using Student's t-test or Mann-Whitney U (for two group comparisons) and the one-way analysis of variance or Kruskal-Wallis (for more than two group comparisons) for continuous numerical data. Categorical data were compared using either χ^2 tests or Fisher's exact tests as appropriate. Health state index scores generally range from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health) were calculated from individual health profiles using crosswalk value sets for Zimbabwe (Reference). Statistical analyses were performed using STATA 16.0 and GraphPad Prism 8.0. A $p < 0.05$ was considered to indicate statistical significance.

Ethical considerations

This was a clinical audit, evaluating standard of care of patients in our clinics. All patients provided written informed consent and the study protocol was in compliance with the ethical guidelines of the *Declarations of Helsinki*.

Results

Sociodemographic characteristics

A total of 74 eligible patients were studied: 41 (55.4%) from Mulago Hospital and 33 (44.6%) from Nsambya Hospital. Majority were female ($n=69$, 93.2%) with a mean $\pm$ SD age of 45 ± 17 years. Thirty-one (41.9%) patients were single, 29 (39.1%) had received tertiary education and 49 (66.2%) were not formally employed. The median (range) monthly income was 300,000 (30,000 – 1,000, 000) Ugandan shillings (UGX). Fifty-five (74.3%) participants received financial support from their children ($n=18$, 24.3%), other family members ($n=15$, 20.3%), their spouses ($n=12$, 16.2%), their parents ($n=7$, 9.5%) or from the church ($n=3$, 4.1%), **Table 1**.

Clinical characteristics

Forty-eight (64.9%) patients had RA, 14 (18.9%) had SLE, and 12 (16.2%) had other rheumatic disorders namely spondyloarthropathy (n=5), systemic sclerosis (n=3), juvenile idiopathic arthritis (n=2), and inflammatory myopathy (n=2). The median (range) duration of illness was 48 (2-420) months. On the day of the clinic visit, patients' self-rated severity of their illnesses was as follows: Controlled (n=10, 13.5%), mild (n=18, 24.3%), moderate (n=29, 39.2%), severe (n=12, 16.2%), and very severe (n=5, 6.8%). The median (range) episodes of disease flares in the past 3 months was 1 (range: 0- 20). Thirty-two (43.2%) patients had at least one co-morbidity. Of these, 23 (71.9%) were RA patients, 4 (12.5%) were SLE and 5 (15.6%) were patients who had other clinical diagnoses.

Disease modifying anti-rheumatic drug therapy

None of the patients was on biologic DMARDs. Majority of the patients with RA were on monotherapy of methotrexate (n=23, 47.9%), those with SLE were mostly either on monotherapy of hydroxychloroquine or in a combination with azathioprine (n= 12, 85.7%), and half of patients with other rheumatic diseases were either on azathioprine or sulfasalazine (n=6, 50%), **Table 1**. The median duration of DMARD therapy was 12 (range: 1-24) months. All 41 patients from Mulago Hospital bought their DMARDs from private pharmacies. On the other hand, 16/33 patients from Nsambya Hospital bought their DMARDS from the hospital pharmacy, 13/33 from private pharmacies and 4 from either private pharmacies or Nsambya Hospital pharmacy. The median (range) monthly cost of DMARDs was 120,000 (12,800 – 2,000,000) UGX. Sixty-four (86.4%) participants reported satisfaction with DMARD treatment. However, 14 (18.9%) participants were on concomitant herbal medication while using DMARDs. Twenty-six (35.1%) participants reported at least 1 adverse drug reactions (ADRs) to the DMARDs. Most ADRs were observed with methotrexate (10/26; 4 patients reported dizziness, 3 weakness, 2 gastrointestinal (GI) disturbances and 1 pulmonary fibrosis), hydroxychloroquine (8/26: 1 visual impairment, 2 rashes, and 5 dizziness), sulfasalazine (4/26: 1 nightmare, 3 GI disturbance), azathioprine (3/26; all 3 reported weakness), and 1 patient reported diarrhea while on mycophenolate mofetil.

Twenty-one (28.4%) patients, most of whom were attending Mulago Hospital Rheumatology Clinic (18/21 (86%) vs. 3/21 (14%), $p=0.01$) were off DMARDs in the week prior to clinic visit.

Health profiles and overall health status

Table 3 and Table 4 summarizes the health indices and overall self-rated health status of the participants across sociodemographic and clinical characteristics. Regarding the health profiles of the participants, 71 (96%) participants reported at least one activity limitation. Any level of problem was reported by 54 (72.5%) participants for mobility, 47 (63.5%) for self-care, 56 (75.6%) for usual activity, 66 (89.1%) for pain and discomfort, and 56 (75.6%) for anxiety/depression. The median health index was 0.675 (range: 0.163 – 0.9). Both health index and overall self-rated health status were higher for patients who received care from Nsambya Hospital compared to Mulago Hospital (0.718 vs. 0.585, $p<0.0001$) and (63.6 vs. 53.7, $p<0.0001$), respectively **Table 3 and 4**. Also, patients with SLE had higher median health index compared to those with RA or other rheumatic disease, **Table 3**. Patients who reported controlled or mild disease, and those who reported satisfaction with medical (DMARDs) therapy had higher health indices and higher overall self-rated health status (all p -values <0.001), **Table 3 and 4**. Conversely, patients who reported concomitant herbal medication use had lower health index (0.558 vs. 0.664, $p=0.03$) and lower overall self-rated health status (47.6 vs. 60.5, $p=0.01$) compared to those who did not report use of herbal medications, **Table 3 and 4**. There was a trend towards patients with co-morbidities having a better overall self-reported health status compared to those without co-morbidities (58.6 vs. 57.7, $p=0.05$), **Table 4**.

Discussion

Understanding PROs influence treatment decisions and inform clinical care in patients with autoimmune rheumatic disease.^{13,14} In the present study, among Ugandan patients with autoimmune rheumatic diseases, over 95% of the patients reported at least one activity limitation. This finding is consistent with the 2020 American College of Rheumatology (ACR) patients survey, where about 83% of people living with a rheumatic disease reported at least one activity limitation as a result of their disease, including ability to exercise, work, and perform physical activities.¹⁵ Our findings suggest that patients with SLE have a better quality of life compared to patients with other autoimmune rheumatic diseases which is in line with prior investigation.¹⁶ Contrastingly, a recent study from Kenya showed that patients with SLE had significantly low health-related quality of life.¹⁷ This is probably because the Kenyan patients had more severe disease, though much younger age than our population. Remarkably, participants with duration of illness of 4 years or less and those who were on DMARDs for less than 1 year had higher health indices. Equally remarkably, overall self-rated health status was comparable across groups and sub groups of illness duration and duration of uninterrupted DMARDs therapy.

Age, disease severity and co-morbidities are important predictors of quality of life of patients with autoimmune diseases.^{17–19} Thus it was not surprising that in our study, patients with controlled or mild disease and those who reported satisfaction with DMARDs had higher health indices and high self-rated health status. Current rheumatic management guidance emphasizes the treat-to-target approach, as patients in remission or low disease activity tends to have a better quality of life indices¹⁴. However, access and affordability of both conventional and biologic DMARDs remains a challenge worldwide.^{15,20} indeed, none of our study participants was on a biologic DMARDs. Lack of access to and non-affordability of DMARDs have negative association with disease activity and a poorer quality of life.²⁰ This is evident in our study where patients attending care in a private hospital with better access to DMARDs had better health indices and overall self-rated health status.

DMARDs are expensive and are unaffordable by most patients. In the 2020 ACR patient survey, the median annual out-of-pocket spending on treatment for rheumatic disease was \$1,000 per year.¹⁵ On average, out-of-pocket expenditure on DMARDs

of our patients was about \$400 per year. This is quite high and explains the high proportion of patients not being on their DMARDs the week prior to their scheduled clinic appoints. In Uganda, much as DMARDs such as methotrexate are on the essential medicine list, they are not routinely available for the care of patients with rheumatic diseases. The heavy financial burden of these diseases and their management explains the huge need for financial support observed in over 70% of our patients. Consequently, patients who are wealthier or have health insurance services are able to access these medicines in private settings and have better adherence and health outcomes as observed in one of the centres in the present study.

One in every 5 patients with rheumatic disease in our cohort reported concomitant use of herbal medication. Regrettably, this was associated with lower health index and lower overall self-rated health status. Despite the fact that ADRs were similar among those who were on herbal medications and those not using herbs, these findings should encourage clinicians to always assess for herbal medication use among these patients and provide appropriate counseling. However, it is unclear whether the poor quality of life of patients on concomitant herbal medication was truly due to negative impacts of herbal medicines on rheumatic diseases or because patients who showed poor response while on DMARDs had uncontrolled disease and therefore sought for herbal remedy for a better disease control. Herbal medication use remains an area of further research among these patients. Known beneficial add-on therapy in patients with rheumatic diseases revolves around optimization of the management of underlying co-morbidities, physical and occupational therapies.¹⁵

Our study has some important limitations. Firstly, we were unable to assess disease specific severity for the different rheumatic diseases. However, we were able to elicit patients-reported disease severity which fairly correlates with disease severity scores. Secondly, we were unable to formally assess for medication adherence using validated tools due to lack of access to license. Thirdly, we were unable to use disease specific health-related outcome measures such as LupusQoL.¹⁶ However, ED-5D-5L has been shown to be a reliable tool for these group of patients.²¹ Lastly, measurements of test-retest reliability were not done because patients were

assessed on only one clinic visit. However, this the first study from Uganda and one of the few in the region to report on quality of life of patients with autoimmune rheumatic diseases receiving DMARDs. Future studies would aim at correlating health indices with disease severity and medication adherence in our setting. At policy level, we need to identify strategies to widely increase availability; accessibility and affordability of DMARDs in Uganda should be explored. It's timely to welcome clinical trials on biologic DMARDs for our patients to evaluate short- and long-term outcomes.

CONCLUSION

In conclusion, over 95% of Ugandan patients with autoimmune rheumatic diseases on DMARDs have at least one activity limitation. SLE patients have better quality of life compared to patients with RA or rheumatic disease. Concomitant use of herbal medication is common and associated with lower health index and lower overall self-rated health status.

Acknowledgement

Mark Kaddumukasa is supported by a grant from the National Institutes Health (K43TW010401 NINDS and Fogarty International Center (FIC). We are indebted to our patients who have become a significant part of us and through whom we are able to enjoy the practice of clinical rheumatology. We appreciate the administrative support from the study sites.

Authors' contribution

All authors significantly contributed to the conceptualization, design, data collection, analysis and interpretation and drafting of the manuscript. The final manuscript was read and approved by all authors.

Competing interests

All authors have no conflict of interest to declare

Funding

None

309

310

References

1. Zochling J, Braun J. Mortality in rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol*. 2009;27(4 SUPPL. 55):S127-30. <http://www.ncbi.nlm.nih.gov/pubmed/19822059>
2. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. *Arthritis Res Ther*. 2009;11(3):229. doi:10.1186/ar2669
3. Schneider S, Junghaenel DU, Keefe FJ, Schwartz JE, Stone AA, Broderick JE. Individual differences in the day-to-day variability of pain, fatigue, and well-being in patients with rheumatic disease: Associations with psychological variables. *Pain*. 2012;153(4):813-822. doi:10.1016/j.pain.2012.01.001
4. Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases — past, present and future. *Nat Rev Rheumatol*. 2017;13(7):443-448. doi:10.1038/nrrheum.2017.95
5. US Food & Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims. Published 2009. Accessed December 13, 2020. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims>
6. Carvajal Bedoya G, Davis LA, Hirsh JM. Patient-Reported Outcomes in Rheumatology Patients With Limited English Proficiency and Limited Health Literacy. *Arthritis Care Res (Hoboken)*. 2020;72(S10):738-749. doi:10.1002/acr.24243
7. Phuti A, Schneider M, Makan K, Tikly M, Hodgkinson B. Living with systemic lupus erythematosus in South Africa: A bitter pill to swallow. *Health Qual Life Outcomes*. 2019;17(1). doi:10.1186/s12955-019-1132-y
8. Usenbo A, Kramer V, Young T, Musekiwa A. Prevalence of Arthritis in Africa: A Systematic Review and Meta-Analysis. Nur Mohamed M, ed. *PLoS One*. 2015;10(8):e0133858. doi:10.1371/journal.pone.0133858
9. Bongomin F, Sekimpi M, Kaddumukasa M. Clinical and immunological characteristics of 56 patients with systemic lupus erythematosus in Uganda. *Rheumatol Adv Pract*. 2020;4(1). doi:10.1093/rap/rkaa011
10. EuroQol - a new facility for the measurement of health-related quality of life. *Health Policy (New York)*. 1990;16(3):199-208. doi:10.1016/0168-8510(90)90421-9
11. Sibhat SG, Fenta TG, Sander B, Gebretekla GB. Health-related quality of life and its predictors among patients with breast cancer at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. *Health Qual Life Outcomes*. 2019;17(1):165. doi:10.1186/s12955-019-1239-1
12. Welie AG, Gebretekla GB, Stolk E, et al. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians. *Value Heal Reg Issues*. 2020;22:7-14. doi:10.1016/j.vhri.2019.08.475
13. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78(6):736-745. doi:10.1136/annrheumdis-2019-215089
14. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78(9):1151-1159.

doi:10.1136/annrheumdis-2018-214819

15. ACR. 2020 Rheumatic Disease Patient Survey Results. Access, Affordability & Lifestyle Challenges for Americans Living with Rheumatic Disease. [simpletasks.org/wp-content/uploads/2020/09/ACR-Survey-2020.pdf](https://www.simpletasks.org/wp-content/uploads/2020/09/ACR-Survey-2020.pdf)
16. Greenfield J, Hudson M, Vinet E, et al. A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). Abu-Shakra M, ed. *PLoS One*. 2017;12(12):e0189840. doi:10.1371/journal.pone.0189840
17. Nyambane E, Genga E, Achieng L, Oyoo O, Otieno FC. Assessment of disease activity and health related quality of life in patients with systemic lupus erythematosus at Kenyatta national hospital. *African J Rheumatol*. 2020;(9.1):A121.2-A122. doi:10.1136/lupus-2020-eurolupus.230
18. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78(6):736-745. doi:10.1136/annrheumdis-2019-215089
19. Wade S, Tikly M, Hopley M. Causes and predictors of death in South Africans with systemic lupus erythematosus. *Rheumatology*. 2007;46(9):1487-1491. doi:10.1093/rheumatology/kem180
20. Bergstra SA, Branco JC, Vega-Morales D, et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. *Ann Rheum Dis*. 2018;77(10):1413-1420. doi:10.1136/annrheumdis-2018-213289
21. Zhang L, Luan W, Geng S, et al. Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China. *BMC Health Serv Res*. 2019;19(1):378. doi:10.1186/s12913-019-4206-y

387 Tables

388 **Table 1: Sociodemographic and clinical characteristics of the participants**

Variable	Freq (%)
Centre, n=74	
Mulago Hospital	41 (55.4)
Nsambya Hospital	33 (44.6)
Age, mean $\pm$SD years	45 $\pm$ 17
≤ 45	39 (52.7)
> 45	35 (47.3)
Sex, n=74	
Female	69 (93.2)
Male	5 (6.8)
Marital status, n=74	
Single	31 (41.9)
Married	22 (29.7)
Widow/er	13 (17.6)
Divorced	8 (10.8)
Education level, n=74	
Informal	6 (8.1)
Primary	21 (28.4)
Secondary	18 (24.3)
Tertiary	29 (39.2)
Employment, n=74	
Formal	25 (33.8)
Informal	49 (66.2)
Financial support, n=74	
Yes	55 (74.3)
No	19 (25.7)
Clinical diagnosis, n=74	
RA	48 (64.9)
SLE	14 (18.9)
Others	12 (16.2)
Duration of illness, median, range (months)	48 (2-420)
≤ 48	40 (54.1)
> 48	34 (45.9)
Self-reported disease severity, n=74	
Controlled	10 (13.5)
Mild	18 (24.3)
Moderate	29 (39.2)
Severe	12 (16.2)
Very severe	5 (6.8)
Satisfaction with medical treatment	
Yes	65 (87.8)
No	9 (12.2)
Use of Herbal medication	
Yes	14 (18.9)
No	60 (81.1)
Adverse drug reactions	
Yes	26 (35.1)
No	48 (64.9)
Charlson co-morbidity index, median , range	2 (1-11)
Hypertension	22 (29.7)

HIV	3 (4.1)
Chronic Heart Failure	3 (4.1)
Diabetes	3 (4.1)
Treatment regimen by diagnosis, n=74	
Rheumatoid arthritis, n=48	
Methotrexate alone	23 (47.9)
Hydroxychloroquine alone	8 (16.7)
Hydroxychloroquine + Methotrexate	8 (16.7)
Methotrexate + Lefluonimide	6 (12.5)
Hydroxychloroquine + azathioprine	2 (4.2)
Hydroxychloroquine + Methotrexate + Lefluonimide	1 (2.1)
SLE, n=14	
Hydroxychloroquine + azathioprine	8 (57.1)
Hydroxychloroquine alone	4 (28.6)
Hydroxychloroquine + Mycophenolate mofetil	2 (14.3)
Others autoimmune rheumatic diseases, n=12	
Azathioprine alone	3 (25.0)
Sulfasalazine alone	3 (25.0)
Hydroxychloroquine alone	1 (8.3)
Hydroxychloroquine + azathioprine	1 (8.3)
Hydroxychloroquine + Methotrexate	1 (8.3)
Hydroxychloroquine + Sulfasalazine	1 (8.3)
Methotrexate alone	1 (8.3)
Methotrexate + Sulfasalazine	1 (8.3)
Source of DMARDS, n=74	
Private pharmacy	54 (73.0)
Nsambya Hospital	16 (26.6)
Nsambya Hospital + private pharmacy	4 (5.4%)
Duration of uninterrupted DMARD therapy, median, Range (months)	
≤12	45 (60.8)
>12	29 (39.2)
Off DMARDS in the last one week	
Yes	21 (28.4)
No	53 (71.6)

389

390

Table 2: EQ-5D-5L frequencies and proportions reported by dimension and level

	MOBILITY N (%)	SELF-CARE N (%)	USUAL ACTIVITIES N (%)	PAIN/DISCOMFORT N (%)	ANXIETY/DEPRESSION N (%)
LEVEL 1 NO PROBLEMS	20 (27.0)	27 (36.5)	18 (24.3)	8 (10.8)	18 (24.3)
LEVEL 2 SLIGHT PROBLEMS	26 (35.1)	23 (31.1)	26 (35.1)	23 (31.1)	26 (35.1)
LEVEL 3 MODERATE PROBLEMS	15 (20.3)	15 (20.3)	20 (27.0)	26 (35.1)	20 (27.0)
LEVEL 4 SEVERE PROBLEMS	12 (16.2)	8 (10.8)	6 (8.1)	17 (23)	8 (10.8)
LEVEL 5 EXTREME PROBLEMS/UNABLE TO DO TOTAL	1 (1.4)	1 (1.4)	4 (5.4)	0 (0)	2 (2.7)
	74 (100)	74 (100)	74 (100)	74 (100)	74 (100)

Table 3: Health indices of the participants across sociodemographic and clinical characteristics

Variable	Freq (%)	Health index Mean (SD)	p-value
ALL, n=74	74 (100%)	0.644 ± 0.164	-
Centre, n=74			
Mulago Hospital	41 (55.4)	0.585 ± 0.177	<0.0001
Nsambya Hospital	33 (44.6)	0.718 ± 0.110	
Age, year			
≤45	39 (52.7)	0.657 ± 0.138	0.516
>45	35 (47.3)	0.632 ± 0.185	
Sex, n=74			
Female	69 (93.2)	0.637 ± 0.162	0.160
Male	5 (6.8)	0.744 ± 0.177	
Marital status, n=74			
Single	31 (41.9)	0.673 ± 0.169	0.633
Married	22 (29.7)	0.629 ± 0.144	
Widow/er	13 (17.6)	0.611 ± 0.212	
Divorced	8 (10.8)	0.628 ± 0.105	
Education level, n=74			
Informal	6 (8.1)	0.675 ± 0.139	0.227
Primary	21 (28.4)	0.594 ± 0.162	
Secondary	18 (24.3)	0.625 ± 0.169	
Tertiary	29 (39.2)	0.686 ± 0.162	
Employment, n=74			
Formal	25 (33.8)	0.672 ± 0.172	0.302
Informal	49 (66.2)	0.630 ± 0.159	
Financial support, n=74			
Yes	55 (74.3)	0.637 ± 0.161	0.528
No	19 (25.7)	0.665 ± 0.665	
Clinical diagnosis, n=74			
RA	48 (64.9)	0.601 ± 0.173	0.007
SLE	14 (18.9)	0.738 ± 0.121	
Others	12 (16.2)	0.704 ± 0.097	
Duration of illness, median, range (months), n=74	48 (2-420)	0.644 ± 0.164	
≤48	40 (54.1)	0.682 ± 0.125	0.029
> 48	34 (45.9)	0.599 ± 0.193	
Self-reported disease severity, n=74			
Controlled	10 (13.5)	0.740 ± 0.112	<0.0001
Mild	18 (24.3)	0.719 ± 0.120	
Moderate	29 (39.2)	0.650 ± 0.158	
Severe	12 (16.2)	0.467 ± 0.090	
Very severe	5 (6.8)	0.572 ± 0.234	
Satisfaction with medical treatment			
Yes	65 (87.8)	0.668 ± 0.145	0.001
No	9 (12.2)	0.472 ± 0.194	
Use of Herbal medication			
Yes	14 (18.9)	0.558 ± 0.231	0.03
No	60 (81.1)	0.664 ± 0.139	
Adverse drug reactions			
Yes	26 (35.1)	0.627 ± 0.181	0.516
No	48 (64.9)	0.653 ± 0.155	

Co-morbidity			
Yes	32 (43.2)	0.642 ± 0.170	0.91
No	42 (56.8)	0.646 ± 0.161	
Source of DMARDS, n=74			
Private pharmacy	54 (73.0)	0.644 ± 0.164	0.196
Nsambya Hospital	16 (26.6)	0.709 ± 0.099	
Nsambya Hospital + private pharmacy	4 (5.4%)	0.649 ± 0.102	
Duration of uninterrupted DMARD therapy, median, Range (months), n=74	12 (1-240)	0.646 ± 0.161	
≤12	45 (60.8)	0.675 ± 0.133	0.042
>12	29 (39.2)	0.594 ± 0.195	
Off DMARDs in the last one week			
Yes	21 (28.4)	0.622 ± 0.185	0.771
No	53 (71.6)	0.652 ± 0.180	

397

Table 4: Overall self-rated health status of the participants across sociodemographic and clinical characteristics

Variable	Freq (%)	Overall self-rated health status Mean (SD)	p-value
ALL, n=74	74 (100%)	58.1 ± 16.7	-
Centre, n=74			
Mulago Hospital	41 (55.4)	53.7 ± 17.2	0.01
Nsambya Hospital	33 (44.6)	63.6 ± 14.3	
Age, year			
≤45	35 (47.3)	58.6 ± 15.6	0.823
>45	39 (52.7)	57.7 ± 17.8	
Sex, n=74			
Female	69 (93.2)	57.6 ± 16.6	0.342
Male	5 (6.8)	65.0 ± 18.0	
Marital status, n=74			
Single	31 (41.9)	57.1 ± 18.9	0.874
Married	22 (29.7)	59.8 ± 15.7	
Widow/er	13 (17.6)	59.6 ± 15.9	
Divorced	8 (10.8)	55.0 ± 12.8	
Education level, n=74			
Informal	6 (8.1)	60.8 ± 20.1	0.849
Primary	21 (28.4)	55.5 ± 14.0	
Secondary	18 (24.3)	59.4 ± 16.2	
Tertiary	29 (39.2)	58.6 ± 18.6	
Employment, n=74			
Formal	25 (33.8)	61.0 ± 16.6	0.290
Informal	49 (66.2)	56.6 ± 16.7	
Financial support, n=74			
Yes	55 (74.3)	58.2 ± 16.9	0.949
No	19 (25.7)	57.9 ± 16.4	
Duration of illness, median, range (months), n=74	48 (2-420)	58.1 ± 16.7	
≤48	40 (54.1)	61.3 ± 15.4	0.079
> 48	34 (45.9)	54.4 ± 17.5	
Clinical diagnosis, n=74			
RA	48 (64.9)	55.7 ± 17.4	0.225
SLE	14 (18.9)	63.9 ± 17.0	
Others	12 (16.2)	60.8 ± 11.4	
Self-reported disease severity, n=74			
Controlled	10 (13.5)	72.5 ± 14.4	<0.0001
Mild	18 (24.3)	65.0 ± 13.1	
Moderate	29 (39.2)	55.5 ± 15.2	
Severe	12 (16.2)	45.0 ± 15.5	
Very severe	5 (6.8)	51.0 ± 15.6	
Satisfaction with medical treatment			
Yes	65 (87.8)	60.8 ± 15.0	<0.0001
No	9 (12.2)	38.9 ± 16.4	
Use of Herbal medication			
Yes	14 (18.9)	47.9 ± 23.2	0.01
No	60 (81.1)	60.5 ± 14.0	
Adverse drug reactions			

Yes	26 (35.1)	57.9 ± 13.4	0.933
No	48 (64.9)	58.2 ± 18.3	
Co-morbidity			
Yes	32 (43.2)	58.6 ± 17.7	0.05
No	42 (56.8)	57.7 ± 16.1	
Source of DMARDS, n=74			
Private pharmacy	54 (73.0)	55.7 ± 17.0	0.829
Nsambya Hospital	16 (26.6)	66.3 ± 14.9	
Nsambya Hospital + private pharmacy	4 (5.4%)	58.8 ± 10.3	
Duration of uninterrupted DMARD therapy, median, Range (months), n=74	12 (1-240)	57.9 ± 17.0	
≤12	45 (60.8)	57.8 ± 15.4	0.922
>12	29 (39.2)	58.2 ± 20.0	
Off DMARDS in the last one week			
Yes	21 (28.4)	58.1 ± 21.5	0.817
No	53 (71.6)	59.4 ± 11.0	

400

401